nnc6019-0001
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 2, 2022 (NCT05442047)
Timeline
Indications
Studied for
Mechanism of action
- TransthyretinINHIBITOR
TTR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07207811 | Phase 3 | Oct 2, 2025 | Novo Nordisk |
| NCT06260709 | Phase 2 | Feb 20, 2024 | Novo Nordisk |
| NCT05442047 | Phase 2 | Aug 2, 2022 | Novo Nordisk |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1